

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Centre for Clinical Practice – Surveillance Programme

### *Recommendation for Guidance Executive*

#### **Clinical guideline**

CG160: Feverish illness in children – assessment and initial management in children younger than 5 years

#### **Publication date**

May 2013

#### **Surveillance report for GE**

February 2015 (2 year surveillance review)

#### **Surveillance recommendation**

Further to the publication of the Evidence Update on CG160: Feverish illness in children, in which no impacts were identified, GE is asked to consider the proposal to not update the guideline at this time.

GE is asked to note that this ‘no to update’ proposal will not be consulted on as described in ‘Developing NICE Guidelines: the manual’, which states that there is no public consultation on the decision at the 2-year timepoint because a decision not to update at this point is verified at the subsequent surveillance timepoint.

#### **Key findings**

			Potential impact on guidance	
			Yes	No
Evidence identified from Evidence Update				✓
Anti-discrimination and equalities considerations				✓
No update	CGUT update	Standard update	Transfer to static list	Change review cycle
✓				

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Centre for Clinical Practice – Surveillance Programme

### Surveillance review of CG160: Feverish illness in children

#### *Recommendation for Guidance Executive*

#### ***Background information***

Guideline issue date: May 2013

NCC: National Collaborating Centre for Women's and Children's Health

#### ***Main findings of the current 2 year surveillance review***

1. The [Evidence Update](#) on CG160: Feverish illness in children was used as the primary source of evidence for this surveillance decision (search dates: 1 October 2012 to 21 August 2014). A summary of the evidence is provided in the Evidence Update.
2. The Evidence Update indicates that there is currently insufficient new evidence to invalidate any of the existing guideline recommendations. The Surveillance Programme therefore recommends no update at this time.

#### ***Ongoing research***

3. Not considered at 2 year review point.

#### ***Anti-discrimination and equalities considerations***

4. None identified through the Evidence Update.

#### ***Implications for other NICE programmes***

5. None identified through the Evidence Update.

***Surveillance recommendation***

6. GE is asked to consider the proposal to not update the guideline at this time. GE is asked to note that as a 2-year surveillance decision this 'no to update' proposal will not be consulted on.

Mark Baker – Centre Director  
Phil Alderson – Clinical Advisor  
Lynne Kincaid – Medical Writer

Centre for Clinical Practice  
February 2015